A New Medicine for Type 1 Diabetes
A dual-acting small molecule for the treatment of type 1 diabetes
This project is developing a new medicine to help people with type 1 diabetes by protecting insulin-producing cells and encouraging them to make more insulin.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Asake Biotechnology, LLC NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11135471 on NIH RePORTER |
What this research studies
Type 1 diabetes causes the immune system to destroy insulin-producing cells in the pancreas, leading to a severe lack of insulin. This new medicine, called MSB-3, is designed to work in two important ways: it aims to protect these vital cells from further damage by the immune system and also encourages them to produce and release more insulin. Early tests in lab dishes with human pancreatic cells and in a mouse model of diabetes have shown promising results, suggesting it could help manage blood sugar levels and reduce the autoimmune attack. This approach seeks to go beyond current insulin therapy by addressing the root causes of cell destruction and insulin deficiency.
Who could benefit from this research
Good fit: Patients with type 1 diabetes, particularly those in earlier stages of the disease where some insulin-producing cells may still be present, could potentially benefit from this type of therapy.
Not a fit: Patients whose insulin-producing cells are completely destroyed may not benefit as much from a therapy designed to protect and stimulate existing cells.
Why it matters
Potential benefit: If successful, this medicine could offer a new way to treat type 1 diabetes by preserving insulin-producing cells and improving the body's natural insulin production, potentially reducing reliance on external insulin.
How similar studies have performed: While insulin therapy has been the standard for a century, recent advancements in protecting beta cells have led to several clinical trials, suggesting this approach builds on a growing area of success.
Where this research is happening
Athens, United States
- Asake Biotechnology, LLC — Athens, United States (Active)
Researchers
- Principal investigator: Wu, Shiyong — Asake Biotechnology, LLC
- Study coordinator: Wu, Shiyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.